Skip to main content
. 2018 May 30;10(6):e7945. doi: 10.15252/emmm.201707945

Figure 2. Prognostic value of qualitative and quantitative assessments of pre‐treatment ctDNA.

Figure 2

  • A, B
    The relationship of pre‐treatment EGFR‐activating mutation levels (allele fractions) with progression‐free survival (PFS) and overall survival (OS) of 19 first‐line TKI‐treated patients where baseline plasma samples (collected before the start of treatment) were available. Patients were grouped into three groups according to their pre‐treatment ctDNA levels, as measured by EGFR‐activating mutation allele fractions: low (< 25% quartile), intermediate (25–75% quartile) and high (> 75% quartile) ctDNA levels. Kaplan–Meier survival curves indicated that patients with high baseline pre‐treatment EGFR‐activating mutant allele fractions were non‐significantly associated with unfavourable (A) PFS (log‐rank P‐value = 0.11) and (B) OS (log‐rank P‐value = 0.16), Cox P‐value of 0.06 for either PFS or OS.
  • C, D
    The prognostic value of concurrent TP53 and EGFR mutations in pre‐treatment plasma samples before EGFR‐TKI therapy. This analysis was performed in 30 first‐line EGFR‐TKI patients where plasma samples were available within 2 months of start of treatment. The presence of both TP53 and EGFR mutations in plasma was associated with a trend of worse PFS (log‐rank P‐value = 0.109, hazard ratio and 95% confidence interval: 0.53 [0.24–1.17]) and significantly worse OS (log‐rank P‐value = 0.035, hazard ratio and 95% confidence interval: 0.43 [0.20–0.97]).